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2012;5:111–21.REPLY: Effectiveness of Antitachycardia
Pacing for Recurrent Ventricular Tachycardia
in ARVCDrs. Santangeli and Marchlinski have asked that we
clarify and expand on the treatment of arrhythmias
described in our recent report (1). We appreciate
this opportunity to respond.
Of the 108 patients with implantable cardioverter-
deﬁbrillators (ICDs) included in the registry, 48 pa-
tients had 502 sustained and treated episodes of
ventricular arrhythmia. Forty-three patients under-
went antitachycardia pacing (ATP) attempts for
ventricular tachycardia (VT); the other 5 patients
received only shock therapy. The number of ATP
attempts per patient ranged from 1 to 96; 28 patients
had #10 attempts. Forty-two of the 43 patients had
at least 1 successful ATP treatment for VT. Twenty-
seven patients had only successful ATP treatment.
Only 3 patients had more failed ATP attempts than
successful ATP attempts. Thus, programming the
ICDs to ﬁrst deliver ATP resulted in the avoidance of
shock treatment in a signiﬁcant number of patients,
and there were no fatalities. We stand by our
conclusion that “all ICDs should be programmed for
ATP, even for rapid VT” (1). However, ATP was not
always successful, because 16 patients had at least
1 ATP failure that resulted in an ICD shock. In total,
30 patients had 89 ICD shocks (average: 3; range: 1
to 9). We are not aware of any episodes of
arrhythmia that were excluded; all episodes of
arrhythmias reported to us were included in our
analysis. It is possible that there were episodes of
ICD shocks and ATP that were not reported to us
and thus could not be included in our analysis.
Drs. Santangeli and Marchlinski also requested
details on ICD programming and management of
recurrent VT during follow-up. In this registry, ICD
programming was left to the discretion of the
physician performing implantation and follow-up.
We do not have details regarding the lower rate
programmed for VT or the duration of VT for
which the ICD would have attempted treatment.
Fifty-three of the 108 patients with an ICD were
treated with antiarrhythmic drugs, and the detailshave been reported in another paper (2). Brieﬂy, in
this patient population, 58 patients who were
treated with beta-blockers did not have an increased
or decreased risk of arrhythmia. Treatment with
sotalol (n ¼ 38) was associated with an increased
risk of ventricular arrhythmias, and the 10 patients
treated with amiodarone had a signiﬁcantly lower
risk of ventricular arrhythmias. Fifteen patients
underwentablation.
Drs. Santangeli and Marchlinski commented on the
high efﬁcacy of the combination of endo-epicardial
catheter ablation. We agree that the reported data
show 1-year efﬁcacy of approximately 70%. We also
agree that the best treatment strategy regarding
recurrent VT remains to be determined, especially
with regard to ablation. In the population studied,
there was no attempt to prevent or promote ablation.
Indeed, 15 of the patients underwent ablation during
the study. However, we do not have data on whether
the attempts at ablation were endo-epicardial or on
the efﬁcacy of ablation in these patients.*Mark S. Link, MD
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and Hypertrophic
Cardiomyopathy
Obiter Dictum or More?We read with interest the state-of-the-art paper
on the present and future of hypertrophic cardio-
myopathy (HCM) by Maron et al. (1), well-known
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2561luminaries in the practice of HCM who have
succinctly summarized the contemporary aspects of
this challenging disease for the cardiovascular
community. From genetics to clinical presentation
to the less well-known aspect of transplantation in
HCM, they have touched on the basic aspects of
HCM well. It is also refreshing to read their
description of the emergence of HCM from an era
of misunderstanding, stigma, and pessimism to one
of more optimism; HCM is now believed to be a
treatable cardiovascular disease, with the vast
majority of patients with HCM reaching normal or
near-normal longevity. In addition, Maron et al.
have delineated the risk stratiﬁcation methodology
in HCM, a ﬁeld that can be disconcerting for both
the physician and the patient. We are indeed
pleased to see this inﬂuential group of physicians
advocating the introduction and acceptance of
cardiac magnetic resonance–delayed gadolinium
enhancement as a risk stratiﬁcation tool in their
“pyramid proﬁle” and arbitration assembly.
We would, however, like to point out the singular
absence in this paper of mention of obstructive sleep
apnea (OSA) in patients with HCM. There have been
rapid advances in the past several years in the un-
derstanding of the association between OSA and
cardiovascular disease and mortality (2). Recent
investigations have shown the coexistence of OSA
and HCM and the important contribution to drug-
refractory symptoms and worsening left ventricular
outﬂow tract obstruction in HCM as a result of
heightened sympathetic nerve activity in OSA (3,4).
The generally stable state of cardiovascular
quiescence in sleep is interrupted in patients with
OSA by intermittent surges in sympathetic nerve
activity, blood pressure, and heart rate.
Several mechanisms elicited by OSA can initiate
and propagate a cascade of noxious stimuli that
initially and over time contribute to progression
of cardiovascular disease in general and repetitive
arrhythmogenic potential in particular in patients
with HCM. Apnea-induced hypoxemia and carbon
dioxide retention in OSA lead to autonomic dysregu-
lation, precipitating increased sympathetic nerve
activity, and parasympathetic withdrawal. These
lead to peripheral vasoconstriction, myocyte injury
and necrosis, renal retention of salt and water, and
increased renin-angiotensin-aldosterone activity, all
of which contribute to both arrhythmogenesis in
HCM and its symptomatology. Furthermore, altered
adrenergic signaling, a key feature of HCM, is also
seen in OSA; indeed, beta-adrenergic receptor inhi-
bition is the most common therapy for symptom re-
lief. Apnea-induced hypoxemia also causes increasedoxidative stress (increased reactive oxygen species)
and platelet activation, which in turn propagate en-
dothelial dysfunction and hypercoagulability. Both of
these increase the susceptibility of the patient with
HCM and small vessel disease to myocardial ischemia
and its consequent attendant malignant ventricular
rhythms. Recent studies involving patients with
implantable cardioverter-deﬁbrillators have shown
that appropriate device discharge occurs 2- to 4-fold
more frequently in those with OSA than in those
without (5).
In addition to the mechanistic consideration of
apnea-induced hypoxemia in arrhythmogenesis in
patients with OSA and HCM, it is important to
consider the effects of futile inspiratory efforts
against an occluded pharynx; this mechanism is
central to the generation of large negative intratho-
racic pressures. The large increase in negative
intrathoracic pressures affects 3 pathways in patients
with OSA and HCM: 1) increased left ventricular
afterload, decreased left ventricular preload with
a consequent decrease in left ventricular stroke
volume, cardiac output, and increased left ventri-
cular outﬂow tract obstruction; 2) increased left
atrial distention/dilation leading to atrial ﬁbrillation,
which is the most common arrhythmia in HCM;
and 3) increased intrathoracic aortic wall stress,
which is a putative mechanism for increased preva-
lence of aortopathy in patients with HCM (an as
yet undetermined ﬁeld).
In summary, there is evidence from observational
and nonrandomized trial data suggesting a signi-
ﬁcant relationship (not necessarily a causal rela-
tionship) between OSA and HCM symptomatology.
Mechanistic investigations also stimulate us to pro-
pose a true arrhythmogenic role of OSA in HCM in
susceptible patients. Thus, it can be argued, among
others, in obiter dicta that integrating OSA into
the risk stratiﬁcation tool in the “pyramid proﬁle”
and arbitration assembly for sudden death in HCM
would strengthen the current pyramid proﬁle.
However, we understand that the most important
approach to this integration will be to conduct
larger-scale multicenter studies to harmonize this
objective.M. Fuad Jan, MBBS, MD
*A. Jamil Tajik, MD
*Aurora Cardiovascular Services
Aurora St. Luke’s Medical Center
2801 West Kinnickinnic River Parkway, #840
Milwaukee, Wisconsin 53215
E-mail: publishing14@aurora.org
http://dx.doi.org/10.1016/j.jacc.2014.09.043
Letters J A C C V O L . 6 4 , N O . 2 3 , 2 0 1 4
D E C E M B E R 1 6 , 2 0 1 4 : 2 5 5 7 – 6 2
2562RE F E RENCE S
1. Maron BJ, Ommen SR, Semsarian C, et al. Hypertrophic cardiomyopathy:
present and future, with translation into contemporary cardiovascular medi-
cine. J Am Coll Cardiol 2014;64:83–99.
2. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular dis-
ease: an American Heart Association/American College of Cardiology Foun-
dation Scientiﬁc Statement from the American Heart Association Council for
High Blood Pressure Research Professional Education Committee, Council on
Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing.
J Am Coll Cardiol 2008;52:686–717.
3. Eleid MF, Konecny T, Orban M, et al. High prevalence of abnormal nocturnal
oximetry in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol
2009;54:1805–9.
4. Sengupta PP, Sorajja D, Eleid MF, et al. Hypertrophic obstructive cardio-
myopathy and sleep-disordered breathing: an unfavorable combination. Nat
Clin Pract Cardiovasc Med 2009;6:14–5.
5. Bitter T, Westerheide N, Prinz C, et al. Cheyne-Stokes respiration
and obstructive sleep apnoea are independent risk factors for malignant
ventricular arrhythmias requiring appropriate cardioverter-deﬁbrillator
therapies in patients with congestive heart failure. Eur Heart J 2011;32:
61–74.REPLY: Obstructive Sleep Apnea and
Hypertrophic Cardiomyopathy
Obiter Dictum or More?We greatly appreciate the positive comments offered
by Drs. Jan and Tajik regarding our contemporary
review of diagnostic and management strategies for
hypertrophic cardiomyopathy (HCM) (1). However,
Drs. Jan and Tajik point out that we have ignored
the role of obstructive sleep apnea (OSA) in the
clinical course of patients with HCM. On reﬂection,
we agree that it was perhaps an oversight not to
at least mention OSA, given the increasing data
suggesting that OSA may contribute to drug-
refractory symptoms and left ventricular outﬂow
gradients in this disease (2,3). On the other hand,
we believe that it is probably premature to consider
OSA to be a sudden death risk stratiﬁcation markerin HCM, given the limited observational data that
are currently available. Nevertheless, because the
HCM risk factor algorithm remains incomplete (4,5),
additional relevant variables would represent a
signiﬁcant contribution to disease management.
Given its inﬂuence on clinical outcomes in a variety
of cardiovascular diseases, OSA warrants further
investigation in this regard.*Barry J. Maron, MD
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